Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →France's Sanofi said on Wednesday it had licensed an experimental Parkinson's disease drug from South Korea's ABL Bio in a deal worth up to $1.06 billion,…
ABL Bio's lead Parkinson's asset ABL301, partnered with Sanofi, has shown a favorable safety profile and pharmacokinetic data consistent with successful…
Sanofi removed three candidates from its phase 1 pipeline, including SAR446159, a brain-shuttled antibody investigated for Parkinson's disease (ABL Bio's…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
In January 2022, South Korea's ABL Bio granted Sanofi an exclusive worldwide license to ABL301 (later Sanofi code SAR446159), a bispecific antibody pairing an anti-alpha-synuclein antibody with ABL Bio's Grabody-B (IGF1R) blood-brain-barrier shuttle for Parkinson's disease. ABL Bio received $75M upfront (paid February 25, 2022 following U.S. HSR antitrust clearance, making the agreement effective) and was eligible for up to $985M in development, regulatory and commercial milestones plus royalties; ABL led preclinical work and the Phase 1 study while Sanofi took global development. ABL Bio booked a $20M GLP-tox milestone in September 2022 and had received roughly $125M in total payments by mid-2025. The Phase 1 trial (NCT05756920, December 2022-April 2025, 91 healthy adults) completed with a clean safety/tolerability profile, announced September 1, 2025, after which Sanofi assumed trial sponsorship. In January 2026, however, Sanofi removed SAR446159/ABL301 from its Phase 1 pipeline, deprioritizing the program despite the positive Phase 1 safety readout. The license economics already paid to ABL Bio are unaffected, but Sanofi's discontinuation ends the asset's forward development under this agreement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ABL Bio Inc. / Sanofi S.A. (ABL301 license to Sanofi) (this deal) | 2022 | $1.1B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
← Browse all deals · How we score deals
More: 2022 deals · Neurology deals